Navigation Links
Chinese Electrophysiology Market to Grow at a CAGR of 20% Over the Next Five Years

Increasing acceptance of EP and large untreated patient population to drive

market, according to Millennium Research Group

WALTHAM, Mass., June 23 /PRNewswire/ -- The Chinese electrophysiology (EP) market will grow significantly over the next five years, driven by the increasing acceptance of EP ablation for the treatment of cardiac arrhythmias (a disorder that causes abnormal heart beats) and the large untreated patient population in China. According to Millennium Research Group's Chinese and Japanese Markets for EP Mapping and Ablation Devices 2008 reports, the Chinese EP market was valued at approximately $50 million in 2007 and will grow at a compound annual growth rate (CAGR) of 20% over the next five years. This pattern contrasts with the more mature Japanese market, which was valued at $140 million in 2007 and will grow at a CAGR of only 8% over the same period. EP procedure volume growth in Japan will be slower than in China, resulting in slower Japanese revenue growth.

The rapid growth in Chinese EP mapping and ablation devices is due to the rising life expectancy and increasing affluence in China, expanding the number of cardiac arrhythmia patients who can afford to undergo EP ablation treatment. Previously, these patients would have gone untreated, but with increasing wealth, the number of procedures is rising rapidly. Furthermore, EP ablation is fast becoming the primary treatment option for patients who do not respond to pharmaceutical therapy, particularly for those patients suffering from atrial fibrillation (AF), the most common type of cardiac arrhythmia. Because ablation has been identified as an effective treatment for AF, AF is the fastest-growing segment in the EP market.

"The growing popularity of EP ablation, particularly for AF, and the large untreated patient population will drive significant market growth in China," says Anuk Karunaratne, Senior Analyst at MRG. "AF ablation will also grow rapidly in Japan, but because treatment rates in that country are already higher than those in the emerging markets market expansion will not be as rapid."

The Chinese and Japanese Markets for Electrophysiology (EP) Mapping and Ablation Devices 2008 reports provide coverage of the diagnostic and ablation catheter markets and include coverage of all key industry competitors, including APT, Biosense Webster, CryoCath, C. R. Bard, Medtronic, and St. Jude Medical, among others. Global coverage of the EP markets also includes US, Europe, and Brazil.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. High alcohol consumption increases stroke risk among Chinese men
2. Heavy Drinking Boosts Stroke Risk for Chinese Men
3. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
4. Chinese takeaway in the Wadden Sea
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. China Shenghuo Pharmaceutical Holdings, Inc. Opens Showcase 12Ways(R) Chinese Herbal Beauty Salon in October
7. CHRI Receives Approval for Suining Chuan DAR Authentication Trademark From Chinese Government
8. All-State Properties, L.P. Announces Termination of Reverse Merger With Chinese Pharmaceutical Company
9. Rh-Apo2L Named as One of Chinas High-Tech Transforming Products by Chinese Government
10. What are the essential characteristics of serum PG in Chinese?
11. Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: